Vaia Florou is an Oncology physician affiliated with University of Utah. OpenAlex indexes 161 publications with 1,615 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 Circle Of Hope Dr
Salt Lake City, UT 841125550
Telephone
610-202-1638Provider last certified this registry record 28 Oct 2021.
Clinical trials
- Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Partner Therapeutics, Inc.Program year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20254 payments
- Deciphera Pharmaceuticals Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
29.7%Serotonin-3 Receptor Antagonist12.1%Ondansetron Hcl100%Part D≥29 patientsCorticosteroid5.6%Prednisone100%Part D≥11 patients+ 4 more classes in this area
Nervous system
26.8%Atypical Antipsychotic8.9%Olanzapine100%Part D≥13 patientsPhenothiazine7.9%Prochlorperazine Maleate100%Part D≥25 patients+ 3 more classes in this area
Cardiovascular
18.9%Calcium channel blocker6.6%Amlodipine Besylate100%Part D<11 patientsACE inhibitor3.9%Lisinopril100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2022 per NIH RePORTER. The latest:
- Exploration of Novel Mutation Biomarkers to Repurpose EGFRi for Mutant KRAS Colorectal Cancer
University of Utah
FY2022$170,375R21CA252436 - Exploration of Novel Mutation Biomarkers to Repurpose EGFRi for Mutant KRAS Colorectal Cancer
University of Utah
FY2021$221,771R21CA252436
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ACR Appropriateness Criteria® Suspected Primary Bone Tumors: 2024 Update
Journal of the American College of Radiology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”